Topical carbonic anhydrase inhibitors.

Area of Science:

• Ophthalmology
• Pharmacology

Background:

• Glaucoma management requires effective intraocular pressure (IOP) reduction.
• Topical carbonic anhydrase inhibitors offer a novel therapeutic approach.

Purpose of the Study:

• To evaluate dorzolamide as a topical carbonic anhydrase inhibitor for glaucoma treatment.
• To compare its efficacy and safety profile with existing therapies.

Main Methods:

• Clinical trials assessing topical dorzolamide's effect on IOP.
• Comparison with beta-blockers and other ocular hypotensive agents.
• Monitoring for systemic and local adverse events.

Main Results:

• Dorzolamide demonstrated significant IOP reduction, comparable to beta-blockers.
• Excellent additive effects observed when combined with other topical hypotensive medications.
• Minimal systemic side effects, but local reactions (corneal edema, allergic reactions) were noted.

Conclusions:

• Dorzolamide is an effective first-line glaucoma therapy, especially when beta-blockers are contraindicated.
• Its favorable systemic safety profile is advantageous.
• Careful patient selection is needed due to potential local side effects impacting visual acuity and tolerability.